Due to a dedifferentiation of tumor cells, some thyroid carcinomas lose their capability for
radioiodine (RI) concentration. This phenomenon is associated with a worse prognosis and …

De-differentiated thyroid carcinoma is characterized by loss of thyroid-specific functions and
properties. The therapeutic options for this type of thyroid cancer are limited and generally …

Although well-differentiated thyroid carcinomas are usually curable by the combined effects
of surgery, radioiodine ablation and thyroid stimulating hormone (TSH) suppressive therapy …

AIMS: Radio-iodine is effective in treating metastatic differentiated thyroid cancers. In 20% of
cases, however, these tumours fail to take up radio-iodine, and treatment options are then …

Radioiodine (I-131) therapy is of proven efficacy for differentiated thyroid carcinoma.
However, its efficacy relies on specific uptake mechanisms, which may be lost during the …

Background: Retinoic acid (RA) treatment has been used for redifferentiation of metastatic
thyroid neoplasia that have lost radioiodine (131 I) uptake with heterogeneous results. Aim …

For the treatment of differentiated thyroid cancer, surgery, radioiodide therapy, and
thyrotropin-suppressive thyroxine application represent established therapeutic measures of …

Objectives To evaluate the effectiveness of isotretinoin for improving 131I uptake in
recurrent/metastasized thyroid cancer with no/insufficient 131I uptake. Design Retrospective …

Differentiated thyroid cancer is a malignant tumour that has a fairly good prognosis, with
patients surviving for many years. Multimodal therapy with surgery, radioiodine therapy and …

Thyroid cancer is a relatively common malignancy with an estimated prevalence of 250, 000
in the US A minority of patients have poorly differentiated thyroid carcinoma that is …